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iiChapter 1
Introduction
According to the World Health Organization’s (WHO) 2003 World Cancer Report [15],
cancer rates are projected to increase by 50% by 2020, resulting in a total of 15 million
new cases of cancer in that year alone. In 2000, malignant tumors caused 12% of all
deaths worldwide, and most countries attribute nearly 25% of their deaths to cancer.
While WHO advocates healthy lifestyle changes and public health action as cancer pre-
vention, projecting that this could prevent nearly a third of cancer cases, the number
of cases which are not preventable by lifestyle change or public health action is still a
signiﬁcant percentage of the world population. Cancer will remain a serious problem for
the immediate future, even if action is taken, and thus it is very important for researchers
to concentrate on this area.
Various sources ([3],[19]) claim that between 40 and 50 percent of individuals diagnosed
with cancer will undergo some sort of radiation therapy treatment, rendering it a highly
consequential subset of cancer research. The primary issue with radiation therapy is
accurately planning a treatment procedure for the delivery device. After imaging has
produced a representation of the internal structure of the patient, a clinician will prescribe
a particular dose to be delivered to the cancerous areas. Unfortunately, it can be very
diﬃcult to non-invasively deliver this dose without causing damage to surrounding organs
and other tissues.
The primary treatment planning problem is determining a delivery plan which uni-
formly doses the cancerous area with an appropriate level of radiation while causing as
little collateral damage as possible.
In this introductory chapter of the thesis, we will provide the reader with a preliminary
background so that subsequent discussion of tools, methods and concepts in the later
portions of the thesis can be accessible and illuminating even to those readers without a
formal background in the relevant topics. We assume for the purpose of this document
only that the reader has a basic understanding of mathematics including integral and
diﬀerential calculus, as well as an interest in the methods underlying treatment planning
for cancer.
The remainder of this chapter will contain techniques and terminology involved with
optimization and cancer research, an introductory discussion of optimization, and the
methods used to generate data for our models. The next chapter will include a high-level
discussion of the tool constructed during this research, including the original Matlab
1inspiration as well as a discussion and demonstration of our tool. The ﬁnal chapter is
intended to be more theoretical in nature, and will contain a technical discussion of the
tool’s implementation as well as a mathematical overview of the algorithm used and the
details of translating the model to the GAMS modeling language.
1.1 Cancer Research
Optimization has been used in many areas ranging from ﬁnancial and business planning to
scientiﬁc applications, including a recent increase of applications in the area of treatment
planning for cancer patients. Previous work has ranged from classiﬁcation of cells as
cancerous or normal (as in [7]) based on expression data, to the design of many diﬀerent
types of models ([17],[14],[13],[8],[5],[1]) to deal with the problem of selecting treatment
schemes for many diﬀerent types of treatment methods. Our work is concerned with an
implementation of one of these model designs.
In this particular section, we will discuss the various methods of delivering radiother-
apy to cancer patients, including underlining which methods our tool is currently able to
design plans for and which methods will require additional optimization outside of the
capabilities of our tool. We also discuss some of the terminology common to discussions
of dose planning, and conclude with a brief review of how data is generated for our tool.
1.1.1 Treatment devices
In recent years a number of diﬀerent methods of delivering external beam radiation
therapy have been developed. The devices all rely on eﬀectively the same idea: deliver
radiation to a patient through some aperture from an encircling device. The primary
diﬀerences which we encounter in each type of device include size and shape of aperture,
method of generating radiation for delivery, and whether the aperture and/or patient are
in motion during the treatment.
While our current research is primarily geared toward one particular method of treat-
ment delivery, we believe that it would be a simple exercise to modify our application to
other methods of delivery.
3D-CRT
Three-dimensional conformal radiation therapy is the device for treating cancer for which
our algorithm is primarily meant to be used. The process of 3D-CRT begins by creating
three-dimensional data sets for each patient via a computed tomography (CT) scan,
consisting of the cancerous area and any adjacent normal anatomy. These data sets are
then divided into voxels, which are grouped into subsets of normal tissue, the PTV, and
various OARs (see below).
The process of planning a treatment for these data involves selecting a subset of dis-
crete angles for the delivery of radiation, choosing the intensity at which the radiation
will be delivered, and designing a conformal, bird’s-eye-view aperture shape for the ra-
diation dose. The discrete angles available are determined by the particular treatment
2mechanism, which consists of linear accelerators using microwaves to accelerate electrons
into a small amount of tungsten.
Each dose releases radiation into the nearby human tissue, causing both normal and
cancerous tissue to lose their ability to reproduce. Normal tissue can adapt over time, but
cancerous tissue is less able. External beam therapy as a whole relies on the capability
of normal tissue to retain its vitality even when exposed to radiation.
Any adverse eﬀects in normal or sensitive tissue can be lessened, however, by delivering
multiple beams of weaker intensity to the tumor. The superposition eﬀects resulting from
these weak beams’ combined intensity when they intersect in the tumor create an area
of relatively high dose in the cancerous tissue, but they deposit a much lower dose in the
normal tissue regions.
The aperture for the radiation beams is created with a series of collimators which
surround the beam and shape it to conform (hence conformal radiation therapy) to the
view of the tumor from the particular angle of the beam. This can be done manually or
automatically; however we do not treat this particular problem here.
IMRT
Intensity-modulated radiation therapy allows a more complex dosage proﬁle than 3D-
CRT. Where 3D-CRT conforms a uniform intensity beam to the shape of a tumor, IMRT
attempts to conform not only its shape but generate dose intensities from each angle to
the speciﬁcs of the tumor. Determining a dose plan for IMRT is a three step process:
1. The ﬁrst optimization that must be performed is the creation of a ﬂuence map,
which determines the varying intensities for each small subset of the tumor silhouette
(called bixels). These intensities may correspond to density of a particular area of
a tumor, presence of sensitive organs between the aperture and the tumor, or a
number of other factors. The sum of these ﬂuence maps is subject to the same
optimizations as the uniform beams in 3D-CRT; that is, attempting to deliver dose
to the proper areas at the prescribed level.
2. Each ﬂuence map is then subject to aperture design - given a set of intensity levels,
what set of apertures and intensities from a certain angle will result in a dose that
closely approximates the ﬂuence map?
Figure 1.1: From left to right, a patient with PTV and OAR structures in blue and red respectively, and
two ﬂuence maps representing diﬀerent treatment plans.
33. Finally, the sequence of apertures must be chosen with respect to the mechanical
constraints of the particular device. Since collimators take time to move, and in
consideration of the patient we wish to minimize treatment time, this selection
problem strives to choose a sequence of apertures that requires the least time to
move from one to the next.
While IMRT has the ability to very precisely conform to the intricacies and oddities of
individual tumors, with the gain of customizability we sacriﬁce a great deal in treatment
time. Each angle requires multiple doses, between which the machine must be recali-
brated, resulting in a very long treatment time during which the patient must remain
still. Also, the treatment planning must necessarily take longer than for 3D-CRT, as the
planning process incorporates three steps rather than just one.
IMAT
Intensity-modulated arc therapy, or IMAT, is similar to 3D-CRT and IMRT in that it
follows the same idea of delivering beams of various intensity to the tumor through
apertures which are conformed to the silhouette of the tumor from the beam’s-eye-view,
or of approximating the IMRT ﬂuence maps. However IMAT diﬀers from these methods
in that it strives to deliver its dose in continuous arcs around the patient’s body, rather
than from discrete angles. That is, whereas most methods of delivery simply position the
device (called the gantry) around the body, select a position, choose an aperture, and
activate their radiation dose, IMAT delivers a continual dose as the gantry rotates.
This introduces an additional problem in planning treatment schemes - we require not
only a selection of positions (arcs rather than discrete angles) and intensities as before,
but also a continuous mapping from aperture to aperture along the path of the gantry to
maintain the conformal nature of the beam. Since the collimators require time to change
position, the more varied the shapes of the apertures are, the slower the gantry will have
to move along its arc, inducing a longer exposure time which will lead to a choice of
either lower intensity or higher dose. Less change in aperture therefore allows a faster
rotation time at a higher intensity.
The primary advantages of arc-based therapy rather than beam-based therapy is the
elimination of the “hotspots” that appear where beams overlap outside of the tumor,
which can result in a star-like shape, and the speed of delivery of dose. Because the
doses are delivered continually rather than discretely, the device does not have to be
recalibrated after every angle. However, the complications inherent in the interdepen-
dencies of aperture shape, gantry rotation speed, arc selection and intensity mean that
while this is a potentially highly eﬀective treatment method, it is computationally much
more demanding than the previously outlined approaches.
Tomotherapy
Tomotherapy takes IMAT to the next logical step. Rather than simply delivering doses
in ﬂat arcs, Tomotherapy creates a helical dose path by rotating the gantry while moving
the patient slowly through the device [9]. The primary advantage of this method of
treatment is that the entire tumor volume can be treated at the same time, without
having to realign the system or the patient.
4Tomotherapy also makes use of image-guided radiation therapy [10]. Like the other
methods of treatment, IGRT makes use of initial imaging through CT, magnetic res-
onance imaging (MRI) and positron emission tomography (PET) to locate the tumor
and guide the initial treatment planning. However unlike the methods discussed above,
IGRT makes additional use of frequent two- and three-dimensional imaging during the
treatment process itself to adjust and reﬁne the initial treatment plan, both in intensity
and in shape.
Figure 1.2: A Tomotherapy treatment device.
The process of IGRT can be applied in addition to any of the methods outlined here.
While we do not address replanning using IGRT in this thesis, our tool could also be
used in this regard.
Stereotactic Radiotherapy
Stereotactic radiotherapy is a method primarily designed for the treatment of tumors and
various vascular ailments in the brain. The patient wears a device directly attached to the
body, designed to keep the aﬄicted region of the body completely still. After this device
is attached (under local anaesthesia), three-dimensional data sets are created as in 3D-
CRT. After the treatment has been planned (which must occur while the patient is still
wearing the device), therapy begins immediately. Because of the immobility imposed by
the devices attached to the patient, stereotactic radiotherapy is a highly accurate method
of treatment; the clinically designated PTV and OAR volumes need not include much
additional margin to account for movement.
Many small doses of radiation are delivered from angles around the body, which con-
verge on the cancerous region, delivering a very low dose of radiation to the normal,
healthy tissue but leaving a high amount of dose in the tumor. This process is repeated
at low dosages many times to avoid damage to the brain, and may aid in the treatment
of inoperable tumors.
Stereotactic radiotherapy diﬀers from 3D-CRT in that the apertures through which
the radiation passes are very small and circular, rather than being conformally shaped to
the silhouette of the tumor. There are two primary devices for the delivery of stereotactic
radiotherapy:
5Gamma Knife Likely the most popular delivery device for stereotactic radiotherapy is
the Gamma Knife, which is used for targets inside the brain. The Gamma Knife delivers
dose via a continually decaying radiation source, focused through tiny apertures in various
types of helmets, which are attached directly to the patient. These helmets vary in their
aperture sizes (larger holes for larger targets) and in their position relative to the patient’s
head, which serves to focus the convergence point at speciﬁc locations.
Figure 1.3: The Gamma Knife Perfexion treatment device.
Linear Accelerator Other forms of stereotactic delivery (for example, the CyberKnife
[16]) use a more standard linear accelerator, which functions in the same way as with
3D-CRT. As with all stereotactic therapy, these delivery devices make use of a helmet
for focusing rather than a conformal aperture.
1.1.2 Terminology
Voxels
A voxel is, quite simply, a small cubic subset of the total volume. Where image processing
will divide a two-dimensional image into small square pixels, clinicians also ﬁnd it useful
to make the same divisions in three-dimensional space. The diﬃculty in dividing a volume
into voxels is the same as dividing a plane into pixels: to balance the processing gains
which arise from dividing a continuous space into a number of small, discrete spaces with
the coarseness of the resulting image. While it may be very easy to do image processing
on a picture with only 16 pixels, much of the meaning is lost. In treatment planning, if
our voxels are too large, we may end up neglecting to protect sensitive areas or failing to
plan a dose to a suﬃciently small tumor.
PTV
The planning target volume, principal tumor volume, primary treatment volume, or PTV,
is the ﬁxed subset of voxels determined by a clinician to contain a cancerous tumor
for treatment. This subset is chosen to account for all possible uncertainties which
the treatment may incur; including internal organ shifting, patient movement during
treatment, and inaccuracies in detection. The PTV should have a high probability of
containing the tumor for the entire treatment.
6Two subsets of this volume not directly referenced in this document but still of impor-
tance to treatment planning are the GTV (gross tumor volume) and the CTV (clinical
target volume). The GTV is the subset of voxels containing the highest density of tumor
cells, and can be thought of as the main body of the tumor. However, since this may not
account for some cancerous cells outside of the high density regions, clinicians typically
add a margin of error to the GTV to create the CTV, which will hopefully contain all
cancerous cells which require treatment.
OAR
Along with the normal tissue and one (or more) PTVs, we also must give special consid-
eration to any organs or tissue areas which are particularly vulnerable to the radiation
delivered in our treatment plan. These areas we term the organs at risk, or OAR. In our
treatment planning, we pay special attention to the dose delivered in these regions; while
our goal is ultimately to eliminate all cancerous cells in the patient’s body, we wish to
cause as little collateral damage to unaﬀected, vital organs as possible.
Dose Plan Evaluation
Once a treatment plan has been designed, it is important to be able to evaluate the
quality of that treatment plan. This is a function primarily of two factors: how well the
plan emulates the prescription from a clinician, and how well it avoids damaging non-
cancerous tissues; other factors such as uniformity of dose are also considered in some
cases. While it’s possible to achieve this in a purely numerical fashion, there are several
common graphical methods which translate the data into a more human-readable format.
Here we describe two of the more common methods, the dose plot and the dose-volume
histogram.
Dose Plot Probably the more intuitive of the two methods, the dose plot is a heat-level
representation of radiation within the body, split into a series of slices of the relevant
volume (see Figure 1.1.1). Beams of dose appear as just that - wide rectangular areas
of heat that dissipate as they make their way through the body. Organs are marked
with simple curves, so that an observer can determine how well the plan’s distribution
matches the prescription in the PTV, and ensure that no important sections of the
OAR are being overdosed. Most usefully, however, the dose plot allows the observer to
immediately detect any streaking introduced by the treatment plan, and all local eﬀects
are clearly visible.
Since dose levels are presented as variations in color, however, it is diﬃcult to tell
from a dose plot alone how well the actual levels of dose conform to the prescribed levels.
While we maintain the dose plot in our arsenal for evaluating regions receiving dose, for
our more numerical analysis, we turn to the DVH.
Dose Volume Histogram The dose volume histogram, or DVH, graphs the levels of dose
in various areas of the body using a histogram scheme (see Figure 2.1). The x-axis
corresponds to the level of radiation dose received by a voxel, and the y-axis corresponds
7to the percent of volume of a particular area receiving that dose. An ideal DVH will
have doses of zero for 100% of normal tissue and the OAR, and a tight bell curve in the
PTV around the prescribed level of dose. Typically, however, curves will be much more
gradual and doses will be more varied within a particular volume.
The dose volume histogram that we use in our application is actually a cumulative
DVH; that is, the y-axis corresponds to the percent of volume receiving at least that level
of dose. In this situation, an ideal cDVH will have again doses of zero for 100% of normal
and OAR tissue with 0% of those volumes receiving anything higher, and a vertical line
in the PTV from 100% of volume to 0% of volume at the prescribed level of dose. Again,
in the typical case these will have more gradual curves, implying a more varied dose level
throughout the volume.
Since we use only the cDVH in our application and not the standard DVH, we will
conventionally refer to the cDVH as the DVH for the rest of the document.
1.1.3 Data Generation
First, we must clarify what our program is not: a complete replacement for a clinician.
In fact, we rely quite heavily on the input of a clinician for preprocessing the data,
evaluating the quality of our solution, and providing any additional constraints required
to improve the solution.
The process begins with a raw data set of three-dimensional information collected from
scans of the patient, with various areas that a clinician has designated as normal, PTV,
or OAR. This data is pre-processed through a Monte Carlo simulation, which generates
a model of how much radiation would reach and deposit in a particular area based on
a variety of factors. We then take this processed data and load it into our own model,
which attempts to choose a dose scheme for our particular method of radiation therapy,
3D-CRT, so that the resulting dose distribution in the patient’s body is as close a match
to that prescribed by a clinician as possible, while carefully avoiding any sensitive areas.
The data used to develop our program is courtesy of D.M. Shepard and his group at
the University of Maryland School of Medicine.
1.2 Optimization
The underlying mathematical concept of the present paper resides in the ﬁeld of opti-
mization. For the beneﬁt of readers who have only a background in radiotherapy dose
planning or cancer research, we have included the following section as a primer on the
concepts we will use later in this document. We also hope that it will prove helpful to
those readers with a strong background in optimization as either a quick refresher in the
relevant areas or in recognition that optimization terminology is not entirely universal.
Problems for which optimization is a useful tool can range from ﬁnding the shortest
commute to work, to creating the most lucrative stock portfolio, to determining the ideal
ratio of lemon to honey in one’s tea; but above all an optimizer wishes to improve the
current result given a certain set of limitations. We cannot create new streets to drive
on or remove other drivers from existing streets (much as we might like to), our portfolio
is subject to the risks of the market, and our teacup has only a limited volume.
8Treating these situations mathematically, we say that to optimize a problem is to min-
imize (or maximize, though for simplicity we consider only minimization in this section)
some objective function subject to constraints on its variables [12].
- objective function: This is an expression that represents the situation which we want
to minimize. Thus we need to create some quantitative measure of the situation –
amount of time or distance of commute, risk vs. reward in our portfolio, or some
measure of the ratio of sour to sweet in our tea – which we can drive to its minimum
(or maximum) in order to create an optimal situation. This expression is written
f(x).
- constraints: The constraints of a problem are any physical, practical, or theoretical
limitations our model must take into account when attempting to drive the objective
to its minimum. If no constraints are present, minimizing f(x) may be a simple
matter of taking derivatives, as discussed in Section 1.1.4. But in most situations,
models may need to take into account constraints ranging from traﬃc patterns and
existing streets to the natural movement of the stock market or just how much room
we have in our teacup. These constraints are also expressed as functions, written as
ci(x), where i is some index from 1 to the number of constraints.
- variables: These are the unknown values contributing directly or indirectly to our
objective function measure which we shall change in order to arrive at an optimal
objective function value. Variables may include which streets to take and what
speed to drive, which stocks to purchase and which to sell, or the amounts of lemon
and honey to add to our tea. These variables we refer to here as simply x.
- parameters: Parameters, as we shall use the term here, are pieces of data speciﬁc
to each instance of a problem which relate to the constraints (but which may vary
between instances of a problem). These may include the length of various roads,
average speeds of traﬃc, or prices of stocks at a given time. Parameters allow single
models to be applied to many diﬀerent situations: our tea tasting model could be
applied to a diﬀerent person with a larger teacup by simply updating the parameters
for volume and taste preferences.
The process of determining the composition of the function, as well as the number and
makeup of constraints, variables and parameters, is called modeling, and the resulting
problem will be referred to from now on as a model.
A general mathematical optimization model can therefore be expressed as follows:
min
x f(x) subject to ci(x) ≥ 0 (1.1)
Note however that the constraints in equation (1.1) are only inequalities (to change a
≤ to a ≥, recall that multiplying by -1 will ﬂip this sign), and not strict. Equality
constraints are allowed, and are in fact used in the model described later in this paper.
Strict inequalities, however, can cause diﬃculties when solving the model - because the
real numbers allow one to get inﬁnitely close to a number without actually attaining it,
a solver that approaches the constraint x < 1 from the value x = 0 may keep increasing
indeﬁnitely and never terminate its search.
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treatment plan that accurately delivers a uniform dose of radiation to the tumor and
avoiding sensitive areas and unnecessary damage to other healthy tissue. Various opti-
mization approaches have been used, ranging from linear programming to a mixed integer
problem to various quadratic and more complex approaches, all of which have a range
of applications, quirks and disadvantages. We now brieﬂy describe the fundamentals of
each type of approach and discuss in greater detail their relationships with the treatment
planning problem.
We wish to emphasize that there is no one best solution to every treatment planning
problem. Each of the types of models described here has been used with results ranging
from merely acceptable to spectacular. The advantages and disadvantages which we enu-
merate here are not then intended to show the inferiority of one algorithm over another;
rather, we merely wish to demonstrate our reasoning in choosing the algorithm which we
use in our tool.
1.2.1 Linear Programming
Linear programming is a subset of optimization that makes the requirement that the
objective function and all constraints be of a linear form. The advantage of linear pro-
gramming is that the area of potential solutions (which we shall call feasible) is a convex
polyhedron, so any maximum value that we ﬁnd is guaranteed to be the global maximum
(the true maximum over all possible solutions of the problem) rather than just a local
maximum (the maximum value in a particular range of solutions, not necessarily over all
solutions); and analogously with a minimum.
A linear program is unsolvable in only two situations: if it is infeasible, or if it is
unbounded. An infeasible program implies that two or more constraints are contradictory
– for example, the combination of x ≥ 2 and x ≤ 1 would yield an empty feasible region.
An unbounded program implies that the feasible region is unbounded in the direction
of the objective – for example, when maximizing an objective, if the only constraint is
x ≥ 2 and increasing x increases the objective value, then the best value of x is ∞ and
the problem is therefore unsolvable. Note that these conditions also apply to other forms
of optimization models.
The simplicity of linear programming, when applied to radiotherapy treatment plan-
ning, is a double-edged sword: the human body is not, in any way, “simple’.’ It becomes
very diﬃcult to restrict one’s algorithms to be solely linear while taking into consider-
ation the complexities inherent in the human body. However, the algorithm that we
have chosen to implement in this tool does exactly that, by making direct use of the
abstractions provided in the form of the dose volume histogram (DVH).
A linear model can make use of either nonlinear preprocessing in the form of a Monte
Carlo simulation of dose distribution within the body or a great deal of data from patient
scans to construct a dose matrix, ¯ D, which is then combined with an angle weight to
determine the dose Di to a voxel i as follows:
Di =
X
b
wb ¯ Db,i
10When combined with the range constraints Li ≤ Di ≤ Ui for some lower bound Li and
upper bound Ui, we impose a linear objective function such as
obj =
X
i∈PTV
γi +
X
i∈OAR
Di
where γi is used to model the diﬀerence between the delivered dose level Di and the
prescribed dose level Pi for the voxel i; that is, by adding the constraints
γi ≥ Di − Pi
γi ≥ Pi − Di
This is in fact a simpliﬁed version of the objective function used in our model.
1.2.2 Mixed Integer Programming
A mixed integer program (MIP) employs use of the discrete integer variables Z ⊂ R as
well as variables in the real numbers. By using this scheme, one can eﬀectively introduce
boolean (true/false) constraints rather than strictly numerical constraints by restricting
the range of a variable to be {0,1}. The constraint and objective functions are still
required to be linear in construction, however. The diﬃculty with MIP models arises in
solving them - generally MIP problems are classiﬁed as NP-hard1.
This integer-variable strategy can also be applied in situations where discrete answers
are required – most notably in problems of personnel management for airlines, where one
employee can only be on one plane at a time; or for vehicle routing, where a single truck
cannot follow multiple roads.
MIPs are at once intuitive for use with the 3D-CRT treatment technique, employing
a certain number of discrete delivery angles with a single dose level at each angle. Since
the amount of time required to provide a dose to a patient from each individual angle is
nontrivial, it may be advantageous to constrain the number of angles from which dose can
be delivered to a small number, known to be achievable in some manageable time, and
provided as a parameter based on the individual situation (a small child, for example,
may be able to tolerate a smaller number of discrete angle treatments than an adult).
For angle weights wi and a vector ¯ wi constraining the maximum weight allowed at
angle i, we can introduce a binary variable yi representing which angles i we are allowed
to use:
wi ≤ ¯ wiyi
and the resulting set of variables yi will enumerate the angles which have been used in the
current solution. Note that these constraints would be used in addition to those outlined
in the previous section.
However, as we have just mentioned, the solution of MIPs is classiﬁed as NP-hard.
This may prove prohibitive when the time of solution is of importance. Also, MIPs are
subject to the same constraint as linear programs, in that the objective and constraint
1Nondeterministic polynomial-time hard (NP-hard) problems are at least as diﬃcult as problems which are considered
NP (nondeterministic polynomial-time). These problems are, intuitively, those for which ‘yes’ answers can be veriﬁed
quickly and simply, though ﬁnding a solution may be quite diﬃcult.
11functions must all be of linear form, so aside from the ability to constrain the number
of angles from which dose can be delivered, they oﬀer very little additional functionality
over LPs.
1.2.3 Nonlinear Programming
Nonlinear programs (NLP), like linear programs, allow all of their variables to move in
the space of real numbers, but their constraint and objective functions may have expo-
nents other than 1. They may also make use of logarithms, exponential functions, and
other nonlinear mathematical functions. These models have the advantage of ﬂexibility
- because they are not restricted to using only linear functions, they can much more
closely model the real complexities of life and more accurately determine a solution to
their model.
Figure 1.4: The nonlinear function y = x
2 sin(x) from x = −.5 to x = 4, which contains two local
minimum values.
Unlike linear programming, however, the space of feasible solutions is not guaranteed
to be convex, since the functions used in the program themselves may not be convex,
and may in fact have multiple solutions which an automatic solver will recognize as
“minimums”, as in ﬁgure 1.2.3. If a model were to contain the function y = x
2 sin(x)
as its objective function with a starting point such that −.5 ≤ x < 1, in order to ﬁnd
a smaller value of the objective, a solver with only local awareness would move in the
decreasing direction toward x = 0. Finding a proven global minimum is an open problem
in NLP.
A simple example of an NLP objective function for use in treatment planning is simply
an extension of the linear objective. Rather than introducing additional constraints and
variables to linearly model an absolute value, we instead consider the squared distance
between the dose level Di and the prescribed dose Pi:
obj =
X
i∈PTV
(Di − Pi)
2 +
X
i∈OAR
Di
However, we are not limited to these simple formulations. NLPs represent the most
ﬂexible of our modeling options, and for this very reason have been used in a number
of treatment planning models. Nonlinear constraints can ﬂatten the dose proﬁles to a
more uniform level in various areas of the dose plot, or make use of a simulated annealing
model to simultaneously optimize the shapes apertures and intensities of beams. These
two types of constraints, while hardly representative of the entire ﬁeld, are discussed in
more detail here:
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The concept of Equivalent Uniform Dose (EUD) [11] was designed to summarize and
report inhomogeneous dose distributions for comparison over a series of studies. Because
of the wide variety of variables in dose delivery and planning, including a wide variety of
normalization criteria that can be applied to the dose itself, until EUD was introduced
there was a risk of ﬂattening the dose-response relationship and missing the ﬁner structure
of the trial data. Any two doses, then, are considered to be equivalent if they cause the
same radiobiological eﬀect, regardless of the actual structure of the dose itself.
The target area is generally assumed to be composed of a large number of independent
clonogens (cloned cells), and the radiobiological eﬀect is given by the expected number
of surviving clonogens. By the methods of EUD, then, two radiation doses are equivalent
if their expected number of surviving clonogens are equivalent.
The equation for approximating EUD was originally suggested by Niemierko [11] as
EUD =
 
1
N
X
i
D
a
i
! 1
a
where N is the number of voxels in the tissue area and Di is the dose to the ith voxel.
The value a, a tissue-speciﬁc parameter which serves as the exponent on the dose and
the inverse exponent on the EUD itself, determines the type of approximation of the
EUD. For a = ∞, EUD is the maximal dose to the tissue area; a = −∞ gives EUD as
the minimal dose; a = 1 gives EUD as the arithmetic mean; a = 0 gives EUD as the
geometric mean.
The objective function for EUD was proposed by Wu et al ([20]), and is a product
of subscores fj for each tissue area. The formulation of this score varies based on the
goal of the optimization - minimization of dose for normal tissues or organs at risk, and
prescription attainment for tumors. This is done by setting the value of EUD0 so that
for the target volume, EUD0 is a desired dose, but for normal structures or organs at
risk, it is the maximal tolerable uniform dose. The value of EUD0 would be determined
experimentally.
A potential advantage of EUD is its convexity property. The EUD function above is
convex for a ≥ 1 and concave for a ≤ 1. Since the normal tissues generally use a value
of a that is greater than 1, and the objective is to minimize the dose to normal tissue,
the convex function is being minimized. For target tissue, generally a is much smaller
than 1, and dose is usually maximized, so we are maximizing a concave function. These
convexity properties would help to speed optimization and guarantee globally optimal
results.
Direct Aperture Optimization
Direct aperture optimization (DAO), as proposed by Shepard et al in [18], involves a
direct optimization of the shapes and weights of apertures using a simulated annealing
algorithm. This is a replacement for more traditional two-step process of optimizing
ﬁrst the weights at each angle and then performing a leaf-sequencing algorithm, as in
the algorithm which we use in our tool. The advantage of this is the elimination of
13the second step, which to a certain extent could provide greater overall control of the
treatment planning; in our tool, the second step is not treated at all, but rather left to
other resources as a time consideration.
The simulated annealing portion of this method uses the Boltzmann cooling schedule
P = 2B
1
1 + elog(nsucc+1)/T
prob
0
(where B is the initial probability of acceptance, T
prob
0 is the rate of cooling, and nsucc is
the number of accepted changes so far) to determine the probability of accepting a change
in leaf position that does not decrease the value of the objective function. By allowing
the objective function to increase, the algorithm strives to eliminate the possibility of
locating a local minimum while missing the global minimum.
As in the algorithm which we employ, this method uses DVH constraints to penalize
overdoses and underdoses. The objective function in DAO is evaluated during the opti-
mization after each change in a leaf position or aperture weight - but not if the change
is rejected, which is a standard feature of any simulated annealing application.
One of the primary advantages of DAO is the wide range of possible intensity levels N
per beam direction, Nn = 2n − 1, where n is the number of apertures. While this means
that if three apertures are used, only seven levels are possible, if six apertures are used,
this number balloons to 63. This allows for a greater level of detail in each individual
beam.
Disadvantages of NLP
As with MIPs, these non-linear models can prove diﬃcult to solve, and time consider-
ations may render these models less useful than a model which can be solved quickly.
More importantly, if the model is not convex as described below, we may not be able to
guarantee that the solution found is in fact the global solution. One of the techniques
common in NLP to discover the global solution in a non-convex program is to solve the
problem multiple times with random starting points, but when dealing with a solution
that is already potentially prohibitively slow, multiple solutions may be completely out
of the question.
While certain algorithms take the issues of convexity into account (as described in
EUD), the complexity of the functions employed in the models may be prohibitive to
eﬃcient and eﬀective implementation. In our early work with NLP, including the two
models outlined above and several other formulations not included here, we found results
to be inconsistent or frustratingly slow; whether due to imperfect implementations or
inferiorities inherent in the models was unclear. For this reason, we returned to linear
programming for our implementation.
1.2.4 Convexity
The concept of convexity as it relates to optimization is crucial when it comes to not
only solving a problem but also evaluating the quality of a solution. With a strictly
convex nonlinear function, ﬁnding the minimum value is simply a matter of setting the
14Figure 1.5: The convex function y = (x − 1)2, a parabola with vertex (1,0).
derivative of the function to zero and solving for the variables. For example, the function
y = (x − 1)2 describes the parabola seen in Figure 1.2.4. To ﬁnd the minimum value of
this function, we simply take the derivative of the function with respect to x:
∂
∂x
y = 2(x − 1) = 2 − 2x
and set this expression equal to zero to ﬁnd that the minimum value of our function occurs
at the point where x = 1, which is easily veriﬁable by inspection of the image. However,
with a non-convex function, there may be multiple points at which the derivative is
zero, or the point at which the derivative is zero may be the maximum rather than the
minimum value. In these situations, there are a number of algorithms available to ﬁnd
the solution, but based on the characteristics of the function, they may be very slow
(undoubtedly slower than our single-step solution for an unconstrained convex function).
If the function contains more than one point at which the derivative is zero, the algorithms
may also report a local maximum rather than a global maximum, resulting in a non-
optimal termination.
Because of these important characteristics - speed of solve and a guaranteed global
solution - our research implements a convex approximation of the relevant functions,
which may or may not be advantageous (see discussion in chapter 3).
1.3 Summary
At this point, the reader should have at least a preliminary understanding of various
types of external beam therapy and their uses in radiation treatment, as well as some
intuition regarding optimization models. We hope that we have synthesized these two
topics suﬃciently so that the reader will also have a sense of the role optimization plays
in the planning stages of radiation therapy.
We have presented this section for the purposes of making this thesis as accessible
as possible to readers in both the areas of optimization theory and cancer treatment
planning research, without presuming a background inclusive of both ﬁelds. Even if the
reader is well-versed in both areas, we hope that this has provided a useful review of
topics relevant to our work as discussed in the next two chapters.
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A GUI Tool for Treatment Planning
It is a readily apparent and accepted fact that most human beings can derive much more
meaning out of an organized and well-executed graph than from well-ordered numerical
data. Magnitudes of variance, average values, trends, and many other characteristics of
data that may be completely lost to the average human in a jumble of numbers become
immediately apparent even to those who lack the training and language to formally
describe what they see. For this reason, nearly every publication that can includes
graphs, plots, and charts of their data rather than a list of the actual numerical data.
This reasoning has motivated scientists for hundreds, even thousands of years to de-
sign visualizations of the data they collect, and radiotherapy treatment planning has
proved no exception. The complexity of data involved and the importance of designing
a high-quality plan under quite possibly severe time constraints mean that it is crucial
to eliminate any overhead possible, including ﬁrst and foremost the overhead of under-
standing and analyzing the quality of a proposed solution. Various types of visualizations
have been proposed, ranging from three-dimensional heat graphs of the areas of the body
aﬀected by radiation to abstracted histograms, completely divorced from anatomical rep-
resentation.
In this chapter, we discuss the advantages of enhancing visualization with an interac-
tive element rather than using graphs only as a post hoc analysis tool. We also highlight
a number of the features of the tool we have constructed, and hope that these discussions
will prove illuminating to the user.
2.1 Original Matlab routines
When we originally began exploring the various types of optimization models that had
been developed, our primary tool for visualizing their outputs was a collection of pre-
existing routines in Matlab. Similar to a subset of the routines available in the CERR
package from the Siteman Cancer Center at Washington University in St. Louis [2] but
developed independently at the University of Wisconsin [6], these routines take as input
the existing data compiled from scans of the patient, as well as a listing of the nonzero
beam weights and the numbered angles from which they will be delivered, and provide
a small variety of graphs for visualization. (Note that these routines have been set up
speciﬁcally for a single device and for application to any other treatment device would
16(a) The dose volume histogram corresponding to a par-
ticular solve.
(b) The cumulative dose volume histogram of the same
solve.
Figure 2.1: Dose volume histograms produced by the Matlab tool, based on solutions from an early
model employing the equivalent uniform dose (EUD) technique. In these graphs, the PTV is shown as
a blue dashed curve, and the OAR as a solid red curve.
require modiﬁcation.)
For ease of use we set up small programs which received beam weight and angle input
from our external models (coded not in Matlab but in a scripting language as part of
the GAMS system - see below) either manually as text or via a proprietary ﬁle format
called the GAMS Data eXchange (gdx) using an in-house interface between GAMS and
Matlab. Using this input as well as the patient scan data, the Matlab routines calculated
dose levels to each voxel and created dose volume histograms, cumulative dose volume
histograms, and dose plots for each set of angles and weights provided.
In ﬁgure 2.1, a dose volume histogram and its corresponding cumulative DVH are
shown. These images display a solution which is not of a particularly good quality, but
that can easily be determined from these graphs - in (a), the curve of the PTV ranges
from nearly 0.9 to 1.1, and in (b), very little of the PTV’s curve follows the idealized
prescription level line at x = 1. What we wish to do is tighten the range of the curve in
(a), or cause the curve to become more vertical in (b), but in order to do so, we must
alter models outside of the visualization routine.
Since these utilities were only useful for post hoc visualization, any observations or
insights gained from the resulting graphs had to be translated numerically, taken out-
side of the program, entered as additional constraints into the models, and reloaded into
Matlab for veriﬁcation. Since this seemed an ineﬃcient and less eﬀective use of the visu-
alization abilities than could be oﬀered, our decision was to incorporate the visualization,
modiﬁcation and resolving steps into one interactive GUI tool.
While the existing visualization routines in Matlab were motivational during the design
phase of our tool, we chose not to use Matlab itself for the implementation of our tool
for two reasons. First, we wished the plots to be directly interactive - that is, we wanted
the ability to place constraints directly on the graph and see, on the same graph, the
results of adding those constraints to the model. Lacking an easy way to implement this
in Matlab, we turned elsewhere. However, another advantage of eschewing Matlab has
17been the reduction in proprietary code - while we are still using a proprietary solver, the
rest of our code is freely available.
2.2 DVH versus dose plot
The dose volume histogram and the dose plot, two of the primary visualization methods
for radiotherapy treatment plans, are described in detail in Section 1.2.2. Each has its
advantages and disadvantages. In this application we have chosen the DVH rather than
the dose plot to represent our data for a number of reasons, including the following:
1. Numerical advantages. The dose plot oﬀers useful intuition regarding relative
dose levels in various voxels. However, what it does not oﬀer is an intuitive, self-
contained comparison between actual dose levels and intended dose levels. While
it would be possible to achieve this comparison by presenting a prescription image
alongside a current dose plan image, the comparison is a matter of diﬀering color
levels, which could prove diﬃcult even to a user with normal vision, to say nothing of
a color-blind user. In the DVH, judging whether doses are close to their prescription
is a simple matter of examining the position of a curve.
2. Ease of interpretation. A prescription DVH is very easy to produce - an OAR
curve which exactly follows the y-axis, and a PTV curve which follows the line y = 1
to the x value of the prescription, at which point it makes a right angle and fol-
lows x =dose to the x-axis. “Good” treatment plans are those which most closely
approximate this prescription; “bad” plans will exhibit much diﬀerent behavior. A
dose plot, however, may appear “good” to an observer, but in fact have an unaccept-
ably high amount of variation within the tumor volume or aﬀect a suﬃciently large
number of OAR voxels so as to be toxic to the patient, all of which must be judged
subjectively, where deﬁnite lines can objectively be drawn on a DVH to prevent this
sort of behavior.
3. Global view. The primary disadvantage of a dose plot over a DVH is that due to
the three-dimensional nature of the dose plot, only small slices of the target volume
can be viewed at once, making a full, global view diﬃcult to conceptualize. The
DVH, however, describes the dose levels in all voxels throughout the entire measured
volume, immediately presenting a global view of the dose proﬁle.
4. Ease of implementation. While a dose plot does present an intuitive view of what
happens inside the body, it is inherently diﬃcult to render - while lines and curves
are much easier. It is also diﬃcult to place meaningful constraints on a dose plot,
aside from specifying further areas to receive certain levels of dose. Our particular
model, being of probabilistic nature (see Chapter 3), in fact does not constrain the
areas in which underdosed or overdosed voxels are allowed; it merely constrains the
number of allowed under- or overdoses in the entire volume, making a DVH much
more intuitive and appropriate for the constraints.
We do not wish to imply, however, that the DVH is completely without its disadvantages.
Typically, DVH constraints (called ﬁrst order stochastic dominance constraints) have
18Figure 2.2: The user interface presented in our tool, including controls for constraining the PTV and
OAR, limiting the number of iterations, weighting the volumes, running solves, clearing new solves and
saving images.
been much more diﬃcult to model - and more importantly, more diﬃcult to enforce.
Also, due to the global nature of the cumulative DVH in particular, it becomes necessary
to model and enumerate all voxels in the volumes, which potentially adds a good deal of
overhead to our time considerations.
2.3 Introducing an interactive GUI tool
This tool, whose inspiration is outlined in the previous section, is intended to be a device
which consolidates the process of visualizing potential plans for radiotherapy treatment,
translating desired adjustments accurately to additional model constraints, resolving the
model with those constraints, and redisplaying the updated plan. For simplicity we
have chosen a single type of graph to display (the cumulative dose volume histogram, or
DVH) and a single underlying model (the Ruszczynski algorithm), though this process
is undoubtedly extensible to other models and visualization techniques.
On startup, the user will observe that our tool’s window has two portions: an upper
graphing area, and a lower control box. When the tool is ﬁrst started up, the graphing
area displays an initial solve of the current model. This initial solve is accomplished
through use of the initial.gms model, as described in Section 2.3.1.
After starting up, the user is presented with a number of options as shown in Figure
2.2; of primary concern are the red and blue buttons marked “Add Point”. Clicking
either one of these buttons and moving the cursor over the graph area of the window
will change the cursor into a crosshair. The user can then place a point on the screen by
clicking. What the point signiﬁes depends on which button the user selected:
- PTV (red): The red Add Point button drops a small, red, upward-pointing triangle
onto the graph in the closest allowable position to the point that the user has clicked
(see below). This point represents a constraint which has been added to the model
for further solves - the user now wishes that the red PTV curve have a y value
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higher percent of PTV voxels (the y value) receive at least that amount of dose (the
x value). The user will observe that the ﬁrst time this button is clicked (and before
the user has placed his point), a point is added at (0,1). This is to give the curve
an anchor point, though additional user-placed anchor points are also recommended
(see Section 2.4.5).
- OAR (blue): The blue Add Point button drops a small, blue, downward-pointing
triangle onto the graph in the closest allowable position to the point that the user
has clicked. Similarly to the PTV, this represents a constraint added to the model,
but rather than constraining the PTV’s curve to be “over” this point, we rather
constrain the blue OAR curve to be “under” it. That is, a lower percent of OAR
voxels receive that amount or more of dose. The ﬁrst time this button is clicked,
two points are added: one at (0,1) and the other at the maximum OAR dose on the
x-axis. The point at (0,1) is an anchor point as with the PTV; the point at (max,0)
is a suggested anchor point.
We note here that all points, including anchor points, can be moved after they have been
placed, though with anchor points we do not recommend this. For the mathematical
details on these tail-shaping constraints, see Chapter 3.
The points placed using these buttons are subject to their own constraints. Since by
deﬁnition our DVH curves are non-increasing, we require the points placed using these
buttons to also mimic that non-increasing behavior. That is, if a user attempts to place a
point at an illegal location, the program will simply place a point at the closest allowable
location to that point. For example, if a user were to attempt to place a point above the
line y = 1 (representing 100% of voxels), a point would simply be placed at that x value
but with a y value of 1. This is actually particularly useful when placing constraints on
the PTV; see Section 2.4.5.
We also wish to note that it is not necessary to place points of both types on the
graph; for further discussion of this, see Section 2.4.4.
After the points have been placed on the graph to the user’s satisfaction, the next
buttons of note are the “Show Line” buttons under both PTV and OAR. Clicking these
buttons will “connect the dots” of either the PTV or OAR points on the graph with a
piecewise-linear green curve. This curve, even moreso than the points which signify its
anchors, describes exactly the constraints which will be imposed - the PTV and OAR
curves should not only be constrained to be over or under the points, but over or under
these green constraint curves as well. If the constraint curves appear more stringent
than required by the situation, additional points can be placed (as long as they maintain
the non-decreasing characteristic of the curves) and the green curve can be re-displayed
by simply clicking the button again. Note that these green constraint curves are NOT
required to be convex.
Once the points and curves are set, there are two more options to consider before a
resolve is begun. The ﬁrst of these options is the iteration count, found in an input ﬁeld
in the upper left corner of the control box. If the user does not choose to enter a value,
the resolve will run for a default of 20 iterations; the user may enter any positive value.
(The merits of various iteration numbers are discussed in Section 2.4.1.) The second
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default to 1, giving equal weight to the PTV and OAR in the solve, but in situations
where a tradeoﬀ is required to attempt constraint satisfaction, weighting will aﬀect which
constraints are solved ﬁrst. (For further discussion, see Section 2.4.3.)
At this point, the constraints have been set, an iteration limit has been chosen, and a
set of weights has been input. At this point, the user is ready to resolve, which is done
by clicking on the “Update Graph” button in the upper right corner of the control box.
At this point, the program initializes a GAMS solve, using saved data from the initial
solve as a starting point, and including the additional constraints as speciﬁed with the
green curve. If the program was started from the command line, the user can observe the
GAMS output in the console. Each iteration as speciﬁed by the program corresponds to
a full GAMS solve; for details of the modiﬁed constraints included in each iteration, see
Chapter 3.
The GAMS runs will end either when the iteration limit has been reached, or a solution
has been found with an error of less than 1×10−5. At this point, the window will refresh
with the new solution delineated in red and blue as before, and the old solution in light
red and light blue. If further modiﬁcations are desired, the user can treat this new
graph as he did the original graph, adding or moving points, redrawing the green curve,
changing iteration numbers and weights, and resolving further. Note that the graph area
will only show the results of the two most recent solves.
Two options remain in the interface which we have not yet discussed. The ﬁrst, on
the button located immediately below Update Graph is a button marked “Clear Graph”,
which removes all updated solves, constraint curves, and reloads the original solution from
startup. It does not remove the points that have been placed on the graph, however; to
remove these, use the “Clear Points” buttons for either PTV or OAR. This way the user
can choose to remove constraints on a single volume rather than having to start over
entirely if he makes a mistake (at this time, there is no option to remove single points
from the graph).
The second remaining option is immediately above the Exit button, and is marked
“Save”. This button causes the current state of the graph area to be saved to a ﬁle called
image.tga in the current working directory. Note that this will overwrite any previous
image.tga ﬁles, and that the ﬁle should be renamed immediately if multiple images are
to be recorded. Because of the availability of this workaround, we did not feel it was
necessary to create a ﬁle naming dialogue for the user inside the program.
2.3.1 Accessing patient data using initdata.gms
In order to apply the present tool to properly processed data, the user must modify the
initdata.gms ﬁle. This scan data should be imported using the $GDXIN function, currently
located on line four of this ﬁle; the user should modify this line to include the path to their
new data ﬁle. All data-speciﬁc modiﬁcations should be made in this ﬁle; all subsequent
models use only the generic data sets PTV, OAR, and Normal. Also any speciﬁc sets
should be speciﬁed here (in our current model, we use prostate, bladder, rectum, and
Normal), and grouped appropriately into PTV, OAR, and Normal. Any modiﬁcations in
these groupings should also be made here (for example, if an organ previously classiﬁed
21as Normal should be reclassiﬁed as OAR or vice versa).
This ﬁle also contains a method for sampling over the normal tissue - since the normal
tissue comprises such a large proportion of the relevant tissue, to speed up the solution
time it has been prudent to reduce the number of normal voxels over which dose is
calculated [4]. Models may also eliminate normal tissue entirely and concentrate only on
the well-being of the OAR and the eﬀective treatment of the PTV.
2.3.2 Getting meaningful and useful results
Aside from producing visual output and optionally images of the solution graph, the tool
also produces a listing of the angles and intensity levels used to generate the weights on
the voxels that comprise the graph. This ﬁle is found in the model’s directory and is
called weights.txt and includes the intensities of radiation that should be used from each
angle to deliver a dose whose proﬁle matches that displayed in the tool.
Also created after a solution is generated is the ﬁle update results.txt, containing the
amount of dose deposited in each of the OAR and PTV voxels, but the usefulness of this
ﬁle outside of its intended purpose of relaying information between the solver and the
display tool is unclear.
2.3.3 Required programs
The current version of our GUI tool is compiled to run only on the RedHat Enterprise
distribution of the Linux operating system; it may be hospitable to other distributions
of Linux but at this stage we cannot guarantee portability. The visual interface was
written with a combination of OpenGL and the Fast Light ToolKit (FLTK) for ease
of implementation, as the focus of the program was not on the aesthetic quality of the
interface but rather on its functionality.
In order to run this tool, it is required that the user have a version of the General
Algebraic Modeling System (GAMS) installed. The systems on which the program has
been tested use a recent version, GAMS 22.7 (though the most recent release at time
of writing is GAMS 23.0). GAMS incorporates a scripting language for the description
of models of the form discussed in Section 1.1, and incorporates commercial solvers for
all types of optimization problems. The ILOG CPLEX solver, or CPLEX, is included in
GAMS and provides solutions for linear programs like the one described by our model
using the simplex method1 (though it also contains options for using various interior
point methods).
2.3.4 Interpreting results
As described in Chapter 1, the shape of a prescription DVH graph for our applications
will feature the blue OAR curve as overlapping the y-axis - that is, 100% of OAR voxels
receive zero dose - and the red PTV curve as a right angle, horizontal along the line
y = 1 and vertical at the x value corresponding to the prescribed level of dose for the
1The simplex method is a popular algorithm for the solution of linear programs. Visually, it moves along edges of
the feasible region until it ﬁnds the optimal solution. For more information, see the following article from Georgia Tech
explaining both linear programming and the simplex method in detail: http://www2.isye.gatech.edu/ spyros/LP/LP.html
22target area. In reality it is impossible to replicate this prescription plot exactly, though
we hope to come as close as possible to approximating it.
When visually evaluating quality of solution, a “better” solution is a set of curves
which closely approximate the prescription DVH described above. The OAR should
remain as close as possible to the y-axis, and any overdose tail should be as low to the
x-axis as possible, translating to only a few voxels receiving a high dose; ideally this curve
will lie under any curve that the user deﬁnes. It may in fact be impossible to achieve an
OAR curve that does not reach nearly up to x = 1 without causing severe damage to the
quality of the PTV, since it is possible that in designating the PTV some voxels from an
adjacent OAR were included in that volume.
As much of the PTV curve should be as vertical as possible, as close as possible to
the prescribed level of dose (normalized in our tool to appear at the value x = 1); ideally
this curve will lie above any curve that the user deﬁnes. Long curves above or below
x = 1 are to be avoided; their presence indicates a large hot or cold spot where the tumor
could be dangerously overdosed or receiving insuﬃcient dose to be eﬀective in treating
it. Our particular tool concentrates on the insuﬃcient dose and provides only the option
to constrain underdose in the PTV; if overdose is in fact an issue, the OAR’s overdose
constraints are easily replicable.
2.4 Features of the GUI tool
Aside from the basic functionality outlined above, the GUI tool includes several behaviors
of particular interest to a user of the tool. These features may help the user to create
better solutions more quickly, or to ﬁnd constraints that more accurately reﬂect the
behavior he wishes to observe. In this section, we describe the motivations behind these
features (and some quirks) and how the user can best take advantage of their functionality.
2.4.1 Number of iterations
In certain situations, time may be a crucial factor in determining the desired quality of
a solution. That is, the situation may arise where a “good” solution now is better than
a “great” solution later, particularly if the relative gains aﬀorded by waiting until later
have a much smaller eﬀect on the quality of the solution. In our tool, though the overall
time to solve is relatively rapid, there are demonstrable diﬀerences in the amount of gain
achieved in the ﬁrst few steps over the gains achieved in the subsequent “adjusting” steps.
As shown in Figure 2.3, the amount of progress made in the ﬁrst iteration may be most
of the relevant progress needed, though the relative quality of the solution after several
more iterations is undeniably higher. In fact, comparing the quality of the solution in
part (b) to part (c), the marginal beneﬁt of additional iterations may in fact be quite
small.
One of the key steps in the solution of our algorithm is the construction of the set
of voxels which violate the given constraints (for details, see chapter 3). The largest
improvement in the number of violating voxels is achieved within the ﬁrst few iterations.
After these iterations, the size (and composition) of this set merely ﬂuctuates slightly
as the solver makes small adjustments to the weights and angles of the radiation beams
23(a) The solution generated after one it-
eration of the algorithm.
(b) The improvement on the solution
in (a) after one more iteration.
(c) The improvement on the solution
in (b) after 10 iterations.
Figure 2.3: A comparison of the progress made by the tool after various numbers of iterations using the
same constraints. In each ﬁgure, the previous iteration’s solution is displayed as the lighter lines.
aﬀecting these voxels. As we would hope, the overall trend of the number of violating
voxels is decreasing, but we have no guarantee that it will decrease every time we run
our algorithm.
Solution
If time is in fact of the essence, we encourage the user to employ lower iteration counts -
on the order of 2 or 3 - which may not satisfy the speciﬁed constraints entirely, but may
reduce the solution time. However, we note here that each additional iteration adds only
a few additional seconds to the solution time, as evidenced here.
Each iteration continues the solution from the point achieved by the previous iteration
(or the initial solve for the ﬁrst iteration) and adds only one or two linear constraints to
the original problem. Linear programming solution restarts are fast when compared to
other types of programs, and so these additional iterations are less expensive than if we
were to employ nonlinear constraints.
2.4.2 Piecewise-linear vs. cumulative normal constraints
The nature of the underlying algorithm and model of our tool is the idea of uncertainty
and probability. We observe in Section 2.1 that the distribution of PTV dose levels in the
dose volume histogram roughly resembles the bell curve of a normal distribution. The
algorithm we use takes advantage of this fact and aims to constrain the proportion of
voxels in a volume receiving a dose less than or greater than some threshold value - that
is, it attempts to constrain the upper or lower tails of the distribution to match that of
some ideal random variable distribution, where the random variable is the level of dose
received by a randomly selected voxel in the volume.
With this in mind, we originally decided to constrain our distributions with exactly
that - a normal random variable distribution as described by user points (see ﬁgure
2.4(a)). As this ﬁgure shows, the distribution on the PTV actually very closely matches
that of the cumulative normal distribution. However, these curves are normal curves
24(a) A solution using a cumulative nor-
mal constraint curve.
(b) A solution using piecewise linear
constraint cuves which approximate
the shape of the cumulative normal
constraint.
(c) A solution using piecewise lin-
ear constraint curves constructed from
similar points.
Figure 2.4: A comparison of the cumulative normal and piecewise linear constraint curves.
Figure 2.5: A series of the normal curves calculated to ﬁt given PTV points, demonstrating the diﬃculty
of accurately controlling the normal distribution constraint curve.
constructed using least squares ﬁtting - they show the normal distribution which most
closely approximates that described by the user placed points. This can create some
diﬃculties in accurately developing constraints; see ﬁgure 2.5.
As we were increasingly frustrated with the diﬃculty of using a normal distribution to
describe our constraints, we abandoned the idea of simulating a random variable entirely
and opted for the much more predictable behavior of a piecewise-linear curve (see ﬁgure
2.4(b),(c)). While this particular curve may not directly correspond to any speciﬁc type
of random variable, we recognize that all our algorithm requires is a distribution to ﬁt,
not a parametric form of a random variable. The theory motivating the algorithm we
have chosen incorporates random variables to shape the dose distributions, but in theory
and in practice we have found it to be extremely eﬀective at achieving desired results.
In fact, a useful side eﬀect of the use of a piecewise-linear distribution over a normal
distribution is a reduction in the amount of inter-iteration calculation. Where the origi-
nal implementation with normal distribution checked for constraint violations at a ﬁxed
number of thresholds (whose position varied at every iteration) and thus had to recalcu-
late the violation constraints for each threshold after every iteration, the piecewise-linear
implementation checks for violations only at the user-speciﬁed points and the violation
constraints can therefore be pre-calculated and stored as constants for the duration of
the run.
25(a) A solution with weight placed on
the PTV constraints.
(b) A solution with weight placed on
the OAR constraints.
Figure 2.6: Demonstrating the eﬀects of weighting on a diﬃcult constraint set - examine in particular
the diﬀerence in the PTV. Both ﬁgures use the same initial solution (shown as lighter curves) and
constraints.
Remarks
While cumulative normal constraint curves are no longer supported in the current version
of the tool, we believe it would be relatively easy to translate the functionality of the
random variable distribution to the current tool if this is desired. We caution against
using purely cumulative normal distributions, however, noting that as shown in Figure
2.4(a), the best-ﬁtting normal curve may not pass through the point (0,1) - representing
the fact that 100% of voxels receive at least zero dose. Since this fact is important to
both the theory and the practice of this mechanism, we suggest exploring other random
variable distributions, such as exponential or geometric.
Future work may incorporate both options for constraints, and allow the user to choose
a type of distribution; however we have not observed any practical advantages of using
normal distributions, since all that the algorithm requires is their shape, which is quite
easily approximated using a piecewise-linear curve.
2.4.3 Regional trade-oﬀs
There are frequently times when, as a user of this tool, one’s eyes will be bigger than
one’s stomach. That is, when providing constraints, the user may ask for more than is
physically possible. In this situation, the volume weights described in Section 2.3 come
into play. By default, we give equal priority to the constraints on the OAR and the PTV,
but if one is determined to be of higher importance than the other, these constraints will
allow the user to express this imbalance.
The interplay between these weights may have diﬀering results. As shown in ﬁgure 2.6,
this particular constraint set has characteristics such that weighting the OAR actually
causes losses in the PTV, whereas putting a higher emphasis on the PTV still allows
some gains to be made in the OAR while nearly satisfying the PTV constraints. We
wish to draw special attention to the correspondence in ﬁgure 2.6(b) between the highest
OAR dose and the lowest PTV dose, which suggests that the PTV and OAR may in fact
share voxels, making a full satisfaction of both constraints impossible.
26(a) A solution with a constraint placed
only on the PTV curve.
(b) A solution with a constraint placed
only on the OAR curve.
Figure 2.7: Demonstrating the eﬀects of constraining only one of the volumes rather than both. The
starting solutions are displayed as lighter curves and are the same in both ﬁgures.
These weighting constraints are of use in such situations; the user will have a much
more intimate understanding of the particulars of each individual situation. If the user
suspects that some of the OAR has in fact been included in the PTV, and that dosing
that particular region would be highly detrimental to the patient, he can weight the OAR
more heavily and willingly sacriﬁce some of the PTV. However, if the user knows that
the tumor has in fact taken over part of the OAR, he can still reduce treatment to some
of the OAR while placing a high priority on dosing the entire PTV adequately.
With the expectation that the user may design constraints describing dose proﬁles
which are, in fact, impossible to achieve, our model includes slack variables for each
of the PTV and OAR (for further details, see Chapter 3). We achieve the diﬀerence
in importance of the quality of PTV or OAR solution by putting more importance on
a smaller slack variable for either the PTV or OAR - a higher weight on the PTV
corresponds to a higher penalty for having a positive slack, and similarly on the OAR.
2.4.4 Constraining only one region
There may arise instances wherein a user is satisﬁed with the initial solution for one
volume but wishes to improve the solution on the other. In this case the temptation may
be to provide constraints on only the PTV or the OAR, in an attempt to reduce solution
time and eliminate the aforementioned tradeoﬀs inherent in the interplay between solu-
tions. However, as we will show, leaving an adequate solution unconstrained can severely
harm the quality of its solution in deference to another volume’s constraints - tradeoﬀs
in solution quality are inherent in the model whether a volume has been constrained or
not.
Both solutions appearing in ﬁgure 2.7 begin from the same initial solution. In 2.7(a),
the OAR curve was deemed adequate and the PTV was constrained; in 2.7(b), the PTV
curve was deemed adequate and the OAR was constrained. However in both situations,
we observe that the unconstrained volume’s solution quality decreased dramatically: in
2.7(a), far more OAR voxels received a far higher dose than in any other solve reproduced
in this paper; in 2.7(b), only the very few voxels at the highest doses even come close to
27receiving the prescribed dose. This is due to the simple fact that a lack of constraints
implies to the model a lack of importance of the quality of the current solution, rather
than satisfaction with the current solution.
Solution
Quite simply, to avoid this issue, we recommend the practice of pinning current solutions;
that is, introducing constraints that mimic the current characteristics of the solution so as
to maintain as many of these characteristics as possible while attempting to improve the
characteristics of the solution for the other curve. In some situations, it is in fact possible
to nearly exactly maintain the quality of one solution curve while making signiﬁcant
improvements to the other (see, for example, ﬁgure 2.3(b)), though in other situations
the user should be advised that tradeoﬀs must occur, as described in the previous section.
2.4.5 Additional anchor points
Before we discuss this particular aspect of our tool, we wish to enlighten the user as to
the nature of the constraints used in our model, as they may provide some insight into
the reasoning behind the advice in this section. The idea behind the constraints is not
necessarily to require the dose distribution curves to out-perform the points placed by
the user, but rather to match or out-perform the area underneath (for the OAR) or above
(for the PTV) the constraint curves. Because of this, however, the user must exercise
caution when placing constraints so as not to introduce areas that he did not intend.
During our use of the GUI tool, we noticed one particular issue with the solver’s
eﬀectiveness: when constraining the PTV, it was diﬃcult to achieve a solution which
did not apparently violate the constraining distribution by a large amount. The dose
distribution on the PTV would usually improve slightly in the direction of the constraints,
but the model would terminate long before an acceptable solution was reached.
However, this was not a consistent problem. Certain PTV constraints would produce
perfectly acceptable solutions, or terminate only on iteration count limit rather than
constraint satisfaction but still produce increasingly good solutions as iteration limits
were increased. This suggested that the problem was not mathematical, but rather one
of perception.
The primary diﬃculty with the algorithm proposed by Ruszczynski is that rather than
constraining the positions of the lines of the distribution, it places its constraints on the
integrals of the distributions. While this does have the advantage of keeping the model
convex and linear, it can result in the aforementioned misunderstandings.
In Figure 2.8(a), the constraining piecewise linear distribution has points at (0, 1) and
(0.967113, 1). The area above the green curve is clearly 0, and only 25 (or approximately
.9%) of the PTV voxels are violating the constraint. In Figure 2.8(b), however, the
constraining piecewise linear distribution has points at (0, 1) and (0.967113, 0.9975).
Even this small change causes the area above the green curve to increase to .0012, and
this area constraint is satisﬁed with 161 (or 5.83%) of PTV voxels violating by an average
of .02 Gy.
Unfortunately, this produces an area issue that is diﬃcult to perceive visually - a
triangle produced by (0.9671×0.0025)/2 has approximately the same area as the rectangle
28(a) A piecewise-linear distribution with zero area. 0.9%
of voxels are violating the threshold constraint, and the
model stopped solving only after the maximum number
of allowed iterations.
(b) A piecewise-linear distribution with nonzero area. 6%
of voxels violate the threshold constraint, but the model
declared all constraints satisﬁed after seven iterations.
Figure 2.8: Two examples of PTV constraining with a very small vertical diﬀerence in the piecewise-
linear curve resulting in a large diﬀerence in the quality of the solution. The light blue and light red
curves show the original solution, and the darker curves depict the current solution.
produced by .06 × .02 (here I approximate the PTV’s area based on average underdose
rather than directly calculating the integral simply for intuition’s sake - this rectangle has
approximately the same area as the triangle created by the distribution). However, as we
see in the ﬁgure, this appears to the user as a gross miscalculation. Unfortunately, this
cannot be solved within the program, as the problem exists entirely in human perception
of area equivalencies (see extensive literature in psychology).
Solution
However, certain user-side solutions can be enacted. If the user desires the outcome
of ﬁgure 1, he should ensure that when he places or moves points on the display that
there is a point exactly on the line y = 1 near the location at which he wishes to begin
constraining. If it is exactly on this line, the green curve will be exactly horizontal.
Because of constraints that the y-values of the points on our piecewise linear curve be
non-increasing, it may be diﬃcult to replace a point on the y = 1 line once it has been
moved; this is easily remedied by simply adding another point directly on the y = 1 line.
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Technical and Mathematical Details
This ﬁnal chapter is intended for readers curious about the internal workings of both the
program and the algorithm it implements. Where the previous two chapters have taken
a broad, high-level approach to our tool, here we will discuss low-level implementation
and mathematical complexities that we have encountered during the research process.
The chapter will explore the technical considerations of the program we developed.
3.1 A cutting plane algorithm
It is interesting to note that according to practitioners of radiotherapy, clinically relevant
eﬀects are not a linear function of dose and irradiated volume according to radiotherapy
practitioners. Niemierko ([11]) also registers his concern with computer optimized plans
and their frequent inhomogeneities, suggesting that the main goal of creating an eﬀective
computer model should be a homogeneous dose distribution across the target area. His
solution was, as described above, a method of equivalent uniform doses, centered on the
idea of removing streaks and cold spots from the dose plot using complex nonlinear con-
straints. Here, however, we argue that it may be possible to eliminate these irregularities
using linear constraints and focusing not on the dose plot, but rather on the DVH.
This algorithm was originally developed as a stochastic approach to shaping dose
distributions. The idea was to simulate the distribution of the dose in the patient with
a random variable, and constrain the tail of the dose histogram to match or outperform
the tail of the random variable distribution. The simple model we use implements a
cumulative normal distribution, given by
cdfµ,σ(x) =
1
2

1 + erf

x − µ
σ
√
2

As described in Chapter 1, we will deal with the patient on two levels of granularity.
The most coarse granularity is the division of the patient into separate volumes, based
on diﬀerent requirements for their dose levels. The normal tissue is not the target of
our dose, but clearly it is preferable not to highly dose such tissue. The PTV is the
cancerous volume which we are seeking to dose as evenly and as close to the prescribed
levels as possible; the OAR is the volume or set of volumes within the patient that would
potentially be compromised by small amounts of radiation and must be avoided when
30planning the dose delivery. The next level of granularity is the voxel, which is a small
cubic volume of a ﬁxed size, and is used to discretize the larger volume so that the dose
levels can be more easily measured.
Due to the physical characteristics of our particular radiation delivery system (3D-
CRT, as described in Chapter 1), our solution will determine a number of ﬁxed angle
beams to use and the intensity (or weight, as we shall refer to it henceforth) at which to
deliver radiation from these angles. The beam weights will be denoted wa, where a is the
angle number, and the dose delivered to the voxel is denoted sumDose(i), where i is the
index of the voxel in question.
We wish to note at this point that for those readers also consulting [3], our equations
will diﬀer from those presented in that paper due to the fact that our cumulative rep-
resentations are reversed. Where our y value denotes the percent of voxels receiving at
least the corresponding level of dose, the source paper’s y value denotes the percent of
voxels receiving up to the corresponding level of dose. This does not aﬀect the meaning
or analysis of the constraints in any way.
3.1.1 Algorithm fundamentals
The algorithm makes use of several analogous components, which diﬀer in notation based
on which tail (overdose or underdose) we are constraining. In this section, we will pri-
marily speak about the underdose tail, while mentioning the analogous components for
the overdose tail. Our tool currently employs the underdose constraints on the PTV only,
and the overdose constraints on the OAR only, but these are simply limitations that we
have chosen for our implementation, not requirements of the algorithm itself.
First, we wish to consider the proportion of voxels in the volume which are receiving a
dose under a threshold value, t, which we treat as the distribution function of a random
variable sumDose(i) corresponding to the dose received by a randomly selected voxel i
in the PTV. This is denoted
G(t) =
card(i ∈ PTV : sumDose(i) ≤ t)
|PTV|
. (3.1)
The overdose constraint is denoted F(t), and can be applied to any of the volumes
in an eﬀort to reduce hotspot tendencies. Applying both F(t) and G(t) to the PTV
simultaneously may in fact have a similar eﬀect to the constraints of EUD as enumerated
above - a more vertical histogram curve corresponds directly to a less varied (and therefore
more uniform) dose over the volume in question.
Given this random variable distribution, the algorithm then requires that at least a
fraction β of the volume Y should receive doses exceeding t, written
G(t) = P{sumDose(i) ≤ t} ≤ 1 − β.
More speciﬁcally, the probability that a voxel receives a dose less than t is less than or
equal to 1−β. The analogous overdose constraint speciﬁes that no more than a fraction
α receive dose exceeding t, and is written F(t) = P{sumDose(i) ≥ t} ≥ 1 − α. The
unfortunate diﬃculty that arises when using such constraints is the non-convexity of the
feasible region deﬁned by G(t) in (3.1). The present algorithm’s solution to this problem
31is to recognize that this is a subset of a broader class of problems; that is, the value
which β takes on can be speciﬁed by a particular random variable distribution to which
we wish to ﬁt our dose distribution curves:
G(t) ≤ Ψ(t) (3.2)
where Ψ(t) has the property Ψ(t) = 1 − β for some underdose threshold value t.
The distribution Ψ(t) (and analogously Φ(t) for the OAR) are given target distri-
butions, chosen by the modeler. Thus for any given value of t, the values of these
distributions can be explicitly calculated. The original article [3] suggests beginning
with a normal distribution; as discussed in Section 2.4.2 these prove too cumbersome
for our implementation and we abandoned the normal distribution in favor of the highly
customizable piecewise linear distribution curve.
The values denoted t in this section are, as noted earlier, the threshold dose values
over or under which we wish to constrain the distribution of dose levels. In our model,
the threshold value for the PTV is denoted T, and the value for the OAR is denoted R.
There is, however, no restriction on the values of t, which allows the modeler to choose
any value at all at which to begin his deﬁnition of “tail” - indeed, in many of the OAR
demonstrations in Chapter 2, we constrain nearly three quarters of the x values achieved
as the overdose tail. Most of our PTV constraints are, however, consigned to only the
very small underdose tail, as the initial solution is already quite close to the desired
conﬁguration. We expect the user will quickly develop an intuition as to appropriate
threshold levels while learning to use the tool.
These constraint types - constraints directly on the distribution functions rather than
on dose areas in the body - are called ﬁrst order stochastic dominance constraints, and
as mentioned above, generally describe a non-convex feasible region. This algorithm,
however, creates a convex approximation of this feasible region using linear constraints
that constrain not the individual values, but rather integrals under the relevant curves.
Z ∞
R
F(t)dt ≤
Z ∞
R
Φ(t)dt (3.3)
Z T
0
(1 − G(t))dt ≤
Z T
0
(1 − Ψ(t))dt (3.4)
Note that the right hand sides of (3.3) and (3.4) can be evaluated explicitly over Φ and
Ψ, which as mentioned above are distributions selected by the modeler. For further
discussion, see Section 2.4.2.
However, we employ the following identities to calculate the integrals of the distribu-
tions F(t) and G(t), noting that as described in (3.1), these functions are the percent of
voxels violating the threshold constraint. Their integrals, then, are the average magni-
tude of violation over the entire volume:
Z ∞
R
F(t)dt =
1
|OAR|
X
i∈OAR
max(0,R − sumDose(i)) (3.5)
Z T
0
(1 − G(t))dt =
1
|PTV|
X
i∈PTV
max(0,sumDose(i) − T) (3.6)
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for the ﬁnal model.
Before we describe our ﬁnal model, however, we note that the max function is not
a linear constraint. In order to maintain status as a linear program, the model instead
removes the max function completely from (3.5) and (3.6), substituting instead
X
i∈Bl
(sumDose(i) − T
l
PTV)
X
i∈Al
(R
l
OAR − sumDose(i))
Where A and B are subsets of the OAR and PTV respectively, containing the voxels
whose current dose level (sumDose(i)) violates the threshold constraints R and T.
To prevent a large number of negative values from masking the violating set, the sums
are no longer performed over the entirety of the PTV or OAR, but rather on a subset of
voxels determined between each iteration to be the currently violating set (see Section
3.2.3 for more details).
The cutting-plane method
Denoting the right hand sides of (3.3) and (3.4) by u(R) and v(T) respectively (since
we replace Φ(t) and Ψ(t) with our chosen distributions and can now explicitly calculate
their values for R and T), we now present the algorithm described in [3] implemented by
our tool. Initial conditions are set as described in Section 3.2.3, using a combination of
user-provided data and values generated from the patient data. The value k is used to
denote the current iteration.
The speciﬁc advantage of this method is that it can be added on to an existing model,
linear or nonlinear. The objective function f(x) and any other constraints x ∈ X not
directly related to our algorithm are intentionally unspeciﬁed (see Appendix A.2 for our
implementation) so as to allow for this ﬂexibility.
Each iteration of this algorithm is centered around the creation and reﬁnement of the
sets A and B as described above. At each iteration l, a new constraint is added for the
PTV and/or OAR corresponding to a threshold point Rl or T l where the integral of the
PTV or OAR distribution violates the goal distribution most. Based on this threshold
value and the doses delivered to each voxel for iteration l’s solution, the algorithm then
selects the subset of PTV or OAR voxels which have dose levels below or above the
threshold value respectively, and these subsets become Bl and Al.
Step 1 Solve the GAMS model which now includes the following constraints:
minf(x) subject to x ∈ X
1
|OAR|
X
i∈Al
(R
l
OAR − sumDose(i)) ≤ u(R
l)
1
|PTV|
X
i∈Bl
(sumDose(i) − T
l
PTV) ≤ v(T
l)
where l = 1,...,k.
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δO = max
t≥R
(
1
|OAR|
X
i∈OAR
max(0,t − sumDose(i)) − u(t)
)
(3.7)
δP = max
0≤t≤T
(
1
|PTV|
X
i∈PTV
max(0,sumDose(i) − t) − v(t)
)
(3.8)
If δO and δP are less than our tolerance level, we stop execution and report a
constraint-satisfying solution; otherwise we continue.
Step 3 Increase k by 1, set Rk to be the maximizer of (3.7) if greater than our tolerance;
set T k to be the maximizer of (3.8) if greater than our tolerance. Calculate the
violating sets A and B to contain those voxels violating these thresholds.
A
k = {i ∈ X : sumDose(i) ≥ R
k}
B
k = {i ∈ Y : sumDose(i) ≤ T
k}
Step 4 Repeat from Step 1.
3.1.2 Creating constraining distributions
Our initial solution to the problem of choosing an appropriate distribution was to employ
standard normal distributions. Given values for t and β that we derived from the user-
provided points, we then ﬁt a normal distribution using a linear regression to satisfy the
requirement that
t − µY = σYz1−β
where µY and σY are the mean and standard deviation, respectively, of the distribution,
and z1−β is the (1 − β)-quantile of the standard normal distribution, which we calculate
using the inverse of the erf function:
z1−β =
√
2
 
erf
−1(β)

We ﬁt this equation using a linear regression. Our model used all user-generated points if
the user provided more than one, and an existing point in the actual initial distribution
if he did not (for OAR, the point with the highest dose value; for PTV, the point with
dose value halfway between the current point and the highest dose value).
However, as described in Chapter 2, we discovered that doing this sort of ﬁtting to user
speciﬁed points was, for lack of a better word, clunky. It was extremely diﬃcult to exert
any sort of ﬁne-grained control over the shape of the distribution, and in particular for the
OAR distribution, the characteristics of a normal distribution did not necessarily match
the physically achievable characteristics of the dose distribution. Most importantly, as
shown in ﬁgure 2.4(a), a true cumulative normal distribution which matches the points
provided by a user may not intersect the point (0,1) - which, in the DVH, implies that
some percent of voxels are not even receiving zero dose, and thus makes very little sense.
Other random variable distributions are possible which follow the characteristics of
the dose distributions more closely - for example, a geometric random variable. However,
34we note that what is important in the model is not the fact that our ideal distribution
is that of a random variable. Instead, all the model is concerned with is the integral of
the distribution between zero and the threshold value (or, for overdose constraints, the
integral between the threshold value and inﬁnity). Thus we have chosen to implement
a piecewise linear constraint curve rather than attempting to ﬁt a random distribution
curve, which has a number of advantages.
The ﬁrst advantage of a piecewise linear curve is intuitiveness. When placing two
points on the graph, we can predict exactly where the piecewise linear curve will connect
the two - an important characteristic, considering the constraints are relative to the curve
as well as the user-placed points. There is no guesswork and very little trial-and-error
involved in directing a curve exactly where the user desires it to go.
Another advantage of the piecewise linear curve is its ﬂexibility. Because it aﬀords
a high amount of local control, the user can create a piecewise linear approximation of
ANY desired random number distribution, and even design distributions which do not
correspond to any existing mathematical expression. By moving to a piecewise linear
distribution, we in fact do not lose any of the functionality aﬀorded by random variable
distributions, and gain quite a bit more.
The ﬁnal advantage of moving to piecewise linear distributions is the ease of calcu-
lating their integrals. Where a normal distribution involves calculus, inﬁnite limits and
a number of dynamic calculations throughout the course of the algorithm, our piecewise
linear integrals can be calculated statically at the beginning of the solution using sim-
ple geometric area formulas: the areas described by a piecewise linear curve are in fact
just the sums of a small number of rectangles and triangles. This helps particularly to
increase the ease of interpretation and solution.
3.1.3 Initial conditions
This algorithm includes speciﬁc instructions regarding several initial conditions relevant
to our implementation. First, the initial violating voxel sets A and B are to be the entire
OAR and PTV, respectively; second, the initial threshold points R (on the OAR) and
T (on the PTV) should be set to be the lowest and highest dose values, respectively, at
which we are constraining.
The sets Ai and Bi we call the “violation” sets for each iteration i, and are held
constant over subsequent iterations. That is, the set A1 will always be the entire OAR,
just as the set B1 will always be the entire PTV, and both will correspond to constraints
using our initial conditions. At the next iteration, another set of constraints will be
added, constraining subsets A2 and B2 of the OAR and PTV to be subject to more
restrictive constraints. These subsets are chosen automatically at each iteration k, and
consist of
A
k = {i ∈ X : sumDose(i) ≥ R
k}
B
k = {i ∈ Y : sumDose(i) ≤ T
k}
where Rk and T k are the aforementioned threshold values. Note that Ak and Bk depend
on the dose delivered at iteration k of the algorithm.
The threshold value R is used in the constraints on the OAR for shaping the overdose
distribution. Its initial value is set to be the lowest dose level at which we wish to begin
35Figure 3.1: The size of the violating set of voxels (labeled B) over 10 iterations.
shaping. Similarly, T is used for the PTV in shaping the underdose distribution, and
initially represents the largest dose level at which we wish to terminate our constraint.
Over the course of the iterations of the model, R will increase toward the highest dose
at which we constrain, while T will decrease toward the lowest dose.
Due to our current setup with a piecewise linear distribution, we can predeﬁne several
possible values for R and T as the points deﬁning our piecewise linear curve, and calculate
the values statically before beginning the optimization.
3.1.4 Drawbacks of the algorithm
In order to maintain the characteristics of the algorithm as a convex linear program,
we make sacriﬁces as far as the direct constraining of doses to voxels. Where models
that make direct constraints on the characteristics of the dose within the body may have
more direct control over the dose proﬁles, we place greater importance on a simple, fast
solution.
The ﬁrst issue that arises is the potential for very small but very radical dose outliers.
As mentioned above, A and B are the violating voxel sets per iteration; as the solution
makes progress, their sizes should evince an overall downward trend, though this decrease
is not required and may not in fact appear at every iteration (see for example ﬁgure 3.1).
Given the threshold R or T, our constraints are concerned with the number of violating
voxels above that particular dose level, and not with their individual dose levels. The
unintended consequence of this is that outside of the threshold dose level, some voxels may
in fact experience an increase (or decrease) in their dose level while the overall number of
overdosed (or underdosed) voxels decreases, satisfying the constraint that the probability
of choosing an overdosed voxel ﬁts the given distribution, but perhaps resulting in health
issues.
Anchor points are provided in our implementation to avoid issues like this in practice,
but as these anchor points are only a feature of our implementation and not of the
algorithm, this is a potential hazard that may result in very small areas of very high or
very low dose. While suﬃciently small areas of OAR areas may be tolerant to high doses,
leaving small areas of the PTV underdosed is a potential health risk and could result in
later regrowth of the tumor.
36Figure 3.2: Examples of constraint satisfaction in the OAR with point-wise violations that are not
considered in the area-based constraints.
The other primary issue with this algorithm that we have not been able to account
for in our implementation - and is therefore an issue of which the users of this program
must be aware (see Section 2.4.5) - is a function of the choices made in order to design
a linear, convex model. The constraints used, as described above, are concerned only
with the areas described by the constraining distribution and the PTV and OAR curves.
That is, constraint satisfaction is merely a matter of area comparison, where the dose
distribution’s tail should be less than or equal to the constraining distribution’s integral,
and pointwise satisfaction of constraints is not at all considered (see Figure 3.2).
1
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i∈PTV
max(0,T − DPTV(i)) ≤
Z T
0
(1 − Φ(t))dt
1
|OAR|
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i∈OAR
max(0,DOAR(i) − R) ≤
Z ∞
R
Ψ(t)dt
Eﬀectively, we constrain the average underdose or overdose, rather than individual voxel
dose levels. However, the issue now becomes that rather than producing small numbers
of extreme outliers (and compensating for them with many voxels which gain enough to
produce a net negative eﬀect on the constraint), we reduce (or increase) the dose level
on all voxels with only very few outliers in either direction.
Why is this an issue? While we do wish to reduce the dose level on all OAR voxels
or move all PTV voxels toward their prescribed dose level, the issue arises not in the
practical biological result, but rather in the result as presented in the graph upon which
we place our constraints.
Shown in ﬁgure 3.2 are two situations wherein the solve terminated before the iter-
ation limit, which means that GAMS considered all constraints satisﬁed to within the
acceptable tolerance. However, at ﬁrst glance the user may think that no, in fact their
constraints have not been satisﬁed, as the curve of the OAR is still above the point they
had placed. What the model is concerned with, however, is the area comparison between
the constraint and the OAR - closer inspection reveals that the areas contained between
the violating OAR and the constraint curve are nearly equal to if not less than the areas
contained between the non-violating OAR and the constraint curve. That is, by moving
far below the constraint curve at some points, the distribution is allowed to move above
it at others.
As discussed in Section 2.4.5, the best way for a user to model around this potential
issue is to add additional “anchor” points to the piecewise linear distribution. When
constraining the PTV, add a point on the line y = 1 at the lowest allowable dose level
37before placing other constraints. Similarly in the OAR, add a point on the x-axis at the
maximum allowable dose level, and shape the tail of the piecewise linear distribution in
a more detailed manner.
3.2 Interfacing with GAMS
Technically speaking our primary issue was interfacing with the GAMS system. In order
to increase the speed of the solver, we used several options within the model itself. First,
since our algorithm involves multiple calls to the GAMS system, we used the option
model.solvelink = 2, which causes the solver subsystem to be invoked using the spawn
method rather than saving and restarting the subsystem at each iteration. Also, in order
to ensure that all solves complete fully rather than hanging up the system, we increased
the number of allowable iterations to 500,000.
During our iteration loop, we ensure that not only are we outside of our tolerance
range and within the iteration limit speciﬁed either by the user or by default, we also
ensure that the previous solution terminated successfully (model.modelstat is less than
or equal to 1). If the previous solution was infeasible, it makes little sense to continue
attempting to solve a model which cannot be feasible, since subsequent iterations only
add constraints; constraints are never removed.
Due to the fact that GAMS is a third-party program, our tool interfaces with GAMS
using text-based model ﬁles (with suﬃxes .inc and .gms) and system calls through the
operating system. Most of the individual solution parameters are provided through ﬁles;
the ﬁles loop.inc and fullmodel.inc in particular hold the majority of the conﬁguration
data. However, we do provide three pieces of information via system calls - the number
of iterations and the weights to the PTV and OAR are given as arguments to the system
call that begins the GAMS solve.
We also receive our output from GAMS entirely via text-based ﬁles; as mentioned
in Chapter 2, each solve terminates with the output of the ﬁles weights.txt and up-
date results.txt. The weights ﬁle is intended for researchers and contains a list of the
weights of each beam, ordered by angle number. The results ﬁle is intended only as
a communicative device between GAMS and the tool, and contains the dose levels as
calculated for each voxel in the PTV and OAR.
While we have chosen GAMS for our optimization solution system due to its ready
availability within our department, ease of use via the GAMS modeling language, and
our own prior knowledge of the system, we acknowledge that the proprietary nature of
the system poses a signiﬁcant deterrent to the portability of our tool. However, we wish
to emphasize the fact that the same solutions can be achieved using non-proprietary
software and internal code, rendering this an entirely self-contained tool.
3.3 Future work
We believe that an important extension of this model and program would accommodate
multiple OAR and PTV volumes. The data underlying the models which generated the
images for this paper are derived from a prostate cancer patient, with a single tumor
38Figure 3.3: An early version of the tool which displays multiple OAR regions (in dark blue) and their
initial dose proﬁles (in light blue).
volume in the prostate, but OAR areas comprising both the bladder and the rectum.
Because these areas have diﬀerent anatomical characteristics, the user may be aware of
diﬀerent tolerance levels for each area, and place more stringent constraints on one than
the other, or a higher priority on satisfying constraints for one volume than the other.
Alternately, were we to be dealing with a patient with multiple PTVs, the prescribed
dose level for one tumor may be much diﬀerent than for the other, necessitating the
multiple PTV representation and constraints.
Inclusion of multiple OAR or PTV regions was actually achieved in an earlier ver-
sion of this tool, but discarded at the time due to the lack of ﬂexibility inherent in that
particular hard-coded representation. Because of the unpredictability of individual situ-
ations (multiple tumors, varying numbers of sensitive organs, etc.), any implementation
of multiple volume representation must in its very nature be a highly conﬁgurable tool,
which interacts with the provided data.
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Implementation Details
This appendix will discuss the basic structure of the source code, as well as methods
for using FLTK, compiling the code, and some references for FLTK. The method of
compiling FLTK currently used necessitates that all C++ source code be contained in a
single ﬁle, resulting in the current source ﬁle length of 1474 lines.
A.1 C++ Source
For ease of discussion and further modiﬁcation, the source code ﬁle fulltrial-pwl.cpp
has been delineated by comment lines into nine sections. All code between these comment
lines will be hereafter referred to as a section. We will refer to all subroutines as methods.
To compile FLTK code, one can use the command /s/fltk/bin/fltk-config --use-gl
--compile filename.cpp; however, for convenience, we have created a Makeﬁle which
is invoked in the standard method as simply make.
Section 1 - Header Files and Global Variables
As this program uses FLTK and OpenGL, the ﬁrst required header ﬁles are FL/gl.h and
GL/glu.h, for basic functionality. All other headers are basic C++ or FLTK libraries,
however the additional ﬁle tgasave.h is required for the image saving capabilities.
The global variables present here exist for simplicity:
- PTV, OAR: vectors which store the current solution curves
- PTVdose, OARdose: vectors which store the current solution values
- oldPTV, oldOAR: vectors which store the previous solution curves
- points: vector of PTVup (index 0) and OARdn (index 1) points shown
- Normal: vector of points describing the piecewise linear constraint for PTV (index
0) and OAR (index 1)
- numPTV, numOAR: number of voxels in PTV and OAR
- mousedownx, mousedowny: last coordinates of mouse click
40- maxval: maximum dose to any voxel in PTV or OAR
- selected, special: store ID of current point to move and current crucial point, respec-
tively
- dragging, placing, choosing: state indicators
- O, P: indicators for OAR vs. PTV
- illegalx, illegaly, illegal2, illegal4: values for bounds checking, used in FLTK
- pi: 3.141592653589793
Section 2 - FLTK Workings
This section is what drives the graphical portion of the program. It creates our own
instance of an FLTK window and includes an OpenGL screen, as well as methods to
manipulate the output to that screen. The drawpoint method renders the PTVup and
OARdn points to the screen, while draw takes care of all of the other rendering issues,
such as the OAR, PTV and piecewise linear curves and dragging and placing PTVup and
OARdn points.
Section 3 - GAMS Result Reader
The primary method in this section, readResults, takes raw data from a newline-delineated
text ﬁle formatted so that the ﬁrst line is the number of voxels in the PTV (stored in
numPTV), the second line is the number of voxels in the OAR (stored in numOAR),
followed by the PTV dose data (PTVdose) and ﬁnally the OAR dose data (OARdose).
Any lines left in the ﬁle after numPTV+numOAR lines have been read are ignored. The
method then creates a cumulative dose volume histogram and stores the data in PTV
and OAR, and ﬁnally redraws the window.
The other method here, getPoints, runs only at the beginning of the program and
serves to check whether the appropriate results ﬁle exists and call the initial GAMS
model for a run if it does not.
Section 4 - ErfInv Functions
These are utility functions, included because C++ libraries contain an erf function but
not its inverse. Erf is deﬁned as:
erf(z) =
2
√
π
Z z
0
e
−t2
dt
and is the standard error function, as well as being easily convertible to determine the
value of a cumulative normal distribution. The functions here were veriﬁed against
Matlab’s built-in erﬁnv function, and provide z given erf (z). This section of code is
not used in the current implementation, but rather remains from the earlier cumulative
normal constraints. This section has been left in the source in the interest of extensibility.
41The erf function described here is the standard erf, however we note that this par-
ticular function is not available in GAMS, where one must instead use errorf. The
relationship between the two functions is as follows:
erf(x) = 2 ∗ errorf
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Section 5 - Image Saving
Unmodiﬁed code courtesy of Rob Bateman, available publicly on the Internet. Stores the
current state of the graph screen (without cursor) as a targa named image.tga. If users
wish to save multiple images in one run, the output images should be renamed between
saves to avoid overwriting.
Section 6 - Integral Calculations
This section contains an analytical method for calculating
1
2
Z T
0
erf

x
√
2

+ 1dx
(the integral for constraining the PTV) though previous versions of the program also
included Simpson’s method, the trapezoidal method, and Simpson’s method of approxi-
mating Z ∞
T

1 −
1
2

erf
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x
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2

+ 1

dx,
(the integral for constraining the OAR) which uses a large multiple of T to approxi-
mate ∞. These methods were used only once, in calculating the initial conditions for
the Ruszczynski GAMS model, and all subsequent calculations were performed within
GAMS. Again, this section remains only in the interest of extensibility.
In another previous implementation, this section also contained a method for calcu-
lating Z ∞
T
e
bxdx =
1
b
(e
b∞ − e
bT)
as an experiment in using exponential distributions which we later abandoned in favor
of the ﬂexibility of piecewise linear distributions. We note that generally b is negative,
so this became 1
b − ebT, since with a negative exponent, ex is 0 at inﬁnity.
Section 7 - Normal Distributions
The ﬁrst method in this section is the utility method, taking the set of either PTVup
or OARdn points and ﬁnding a suitable cumulative normal distribution that reﬂects
their placement. This method makes use of the external GAMS model linreg3.gms to
determine the µ and σ that best ﬁt the distribution of points on the graph screen, and
42returns these values as a std::pair, as (µ,σ). Again, this is a legacy implementation
for use with normal constraint curves; our current piecewise linear curves do not use this
method.
The second method is used for visualizing this normal curve if need be; it takes a
given µ and σ and uses normal.gms to generate a set of 8000 points conforming to this
normal distribution. The set is then read in and analyzed in a manner similar to that
of readResults above, and saved to a vector in the Normal global vector. The rendering
displays either normal curve as a bright green line. This is also for use only with normal
constraint curves, not piecewise linear.
In a previous implementation, this section contained two additional methods for ﬁtting
and drawing an exponential curve to the OAR points. The ﬁtting method calls an external
GAMS model linregE.gms to determine the best exponent b when forced to observe a
coeﬃcient of 1, and the drawing method calculates all points on the curve directly using
the function y = ebx.
Section 8 - FLTK Button Functions
All button functions as described in section 1.2 are implemented as callbacks in this
section. The format of a callback is speciﬁed by FLTK as void callback (Fl Widget*
w, void* v). As seen in FLTK documentation (available online), these can be used to
provide arguments to the callbacks, but we avoid that in the interest of simplicity.
The callback methods contained here are as follows:
- cb addPup, cb addOdn: enter placing state for adding PTVup or OARdn points
- cb rmPup, cb rmOdn: remove all PTVup or OARdn points
- cb chooseP, cb chooseO: select a crucial point
- cb restart: run the Ruszczynski algorithm using points on screen
- cb normalP, cb normalO: sort user-deﬁned points by x coordinate and draw the
corresponding piecewise-linear curves (method names remain from previous imple-
mentations using normal distributions)
- cb save: save current state of graph screen as image.tga
- cb refresh: clear all normal curves and restore initial data from startup
- cb quit: restore initial data and exit program
All included ﬁles in the cutting plane algorithm are written dynamically by the method
cb restart. Any modiﬁcations to the algorithm loop, intitial data, or constraints should
be made in this callback method; any modiﬁcations made to the ﬁles themselves will be
overwritten on the next run of the program. This allows the model to reﬂect the user’s
input more accurately.
Section 9 - Main
This method uses getPoints i to get the initial solve data, initializes the global variables,
builds the FLTK window, and lastly runs the program using the all-important Fl::run().
43A.2 GAMS Source
Much of the critical GAMS source code is contained in loop.inc, which is written by
the above callback method cb restart. The bare bones of the code are contained in
fullmodel.gms, which is also run by cb restart.
File 1 - fullmodel.gms
This ﬁle contains the objective function (objective), as well as the voxel-speciﬁc dose
calculator (cons(I,J,K)) and a pair of constraints to enforce an allowable range for the
PTV dose (penUn(I,J,K) and penOv(I,J,K)). The allowable range is Tu to To, and the
objective function currently minimizes the number of voxels in the PTV receiving dose
outside of this range.
The model then includes the relevant constraints for PTV and/or OAR, as written
by the GUI program and based on the PTVup and OARdn points on the screen. If no
points are present for one of PTV or OAR, no constraint on that volume is included.
The rucz.solvelink = 2 option controls the behavior of the solve statement later in
the model. The 2 option starts the solution by spawning a new instance of GAMS instead
of instructing GAMS to save its state, restart, solve, and reload itself upon completion
(as is the default). The end eﬀect of this option is to signiﬁcantly speed the raw time it
takes to solve the GAMS model.
The remainder of the model includes the solution loop, displays the ﬁnal δ values after
card(iter) iterations, and prints the voxel dose weights to the ﬁle results.txt for the GUI
program to read.
File 2 - loop.inc
This ﬁle contains the primary functionality of the Ruszczynski algorithm. Every iteration,
it performs the following tasks:
(1) Alters the dynamic iteration sets to include the current iteration
(2) Determines the sets A and/or B of violating voxels for the current iteration
(3) Solves the model with all current information
(4) Checks to see if the model has solved successfully, exits if infeasible or unbounded
(5) Determines the maximum δ value for PTV and/or OAR
(6) Retrieves the new rhs value for PTV and/or OAR
Upon exiting the loop, the model displays the maximum remaining δ values, the points
at which it enforced the constraints, and the rhs values for all volumes used.
List of Scalars
- littleT: a variable which takes on values in the range of the integration for updating
δ after solving
44- it: number of intervals over which to calculate δ
- int(it): the integer value of the iteration (1-20)
- result: a variable for calculating the integral of the distribution
- up, lo: the upper and lower bounds for integrating the distribution
- sigmaP, sigmaO: the standard deviation values for the distributions of PTV and
OAR, respectively
- muP, muO: the mean values for the distributions of PTV and OAR, respectively
- maxdeltP, maxdeltO: the δ values for PTV and OAR, respectively
- coeﬀP, coeﬀO: the coeﬃcient for the analytical calculation of the integral, given by
(σ
√
2/2)
- big: a variable for calculating the integral of the OAR distribution, eﬀectively the
value of the function at inﬁnity
- v: a variable for choosing an appropriate approximation for inﬁnity in the OAR
integral
- s1,s2,h: variables for calculating the Simpson’s approximation for inﬁnity, depre-
cated
- d: number of intervals for calculating Simpson’s approximation, deprecated
- evens(d), odds(d): integer values of the d set, deprecated
- modstatus: determines the state of the solution so that we can exit the loop if the
model has not solved properly
A.2.1 GAMS Models
The following code is the linear GAMS model our implementation uses to create an
initial solution for the tool to improve upon, contained in initial.gms. Any model, linear
or nonlinear, can be substituted here; if quality of initial solution is unimportant, random
weights could be assigned and all optimization could be performed within the tool itself.
$title LP Radiation Treatment for Visualization
option limrow = 0, limcol = 0, solprint = off;
* get dose matrix and sets
$include initdata.gms
* threshold values
scalar To ’overdose threshold’ /1.001/;
scalar Tu ’underdose threshold’ /0.999/;
45variable obj;
positive variables w(nAngle), sumDose(I,J,K), delta(I,J,K);
equations defobj, cons1, penU, penO;
* basic LP model
defobj..
obj =e= (1/card(PTV))*sum(PTV(I,J,K), delta(I,J,K));
* linear dose definition
cons1(I,J,K)$(PTV(I,J,K))..
sumDose(I,J,K) =e=
sum((nAngle, nWedge), Dose(I,J,K,nAngle,nWedge)*w(nAngle));
* underdose penalty
penU(PTV(I,J,K))..
delta(I,J,K) =g= Tu-sumDose(I,J,K);
* overdose penalty
penO(PTV(I,J,K))..
delta(I,J,K) =g= sumDose(I,J,K)-To;
model basic /defobj, cons1, penU, penO/;
solve basic using lp minimizing obj;
In this initial model our objective function deals only with the PTV, simply for expe-
diency. Our objective function for the cutting plane algorithm incorporates not only the
PTV but also two weighted slack variables corresponding to unsatisﬁed PTV or OAR
constraints.
A.2.2 Objective functions
Finally we list here a series of objective functions, linear and nonlinear, which we have
used in the course of the research, and which are all of potential use with this algorithm:
obj =e= (1/card(PTV))*sum(PTV(I,J,K), delta(I,J,K))
+ sum(oL, \%oarweight\%*slackO(oL))
+ sum(pL, \%ptvweight\%*slackP(pL));
This is the objective function which we currently use. If further computation is not an
issue, the delta values (magnitude of violation outside of a small boundary around the
prescription) could be calculated for the OAR and also considered in this function.
obj =e= sum(TISSUE, sumDose(TISSUE));
This crude objective function simply looks to minimize the dose to the entire body
(TISSUE being composed of the PTV, OAR, and Normal tissue in this instance) while
paying no attention to the prescription levels for the PTV.
46obj =e= sum((nAngle,nWedge), Adose(nAngle,nWedge)*w(nAngle));
Adose is in this case a parameter corresponding to the sum of all values in the dose matrix
for each angle and wedge (a wedge being a device used for altering the ﬂow of radiation;
our models included a variable to allow for these but never utilized them). The only
variable here was then the weight for each angle, resulting again in a linear objective.
obj =e= (1/(1+(EUDzero(’PTV’)/eud(’PTV’))**a(’PTV’)))*
(1/(1+(eud(’OAR’)/EUDzero(’OAR’))**a(’OAR’)))*
(1/(1+(eud(’Normal’)/EUDzero(’Normal’))**a(’Normal’)));
As described in Section 1.2.3, the equivalent uniform dose nonlinear model (EUD) takes
several forms; this was the ﬁrst we used. For others, see [11] and subsequent work.
(Recall that in GAMS notation, the ** symbol represents an exponent, analogous to ∧
in C and other similar languages.)
These four objective functions represent only a small subset of the possible objectives
for use in radiotherapy treatment planning, and we wish to stress that any objective and
model may be combined with the algorithm in our tool, simply by modifying our model
ﬁle fullmodel.gms.
Integral Implementation
In the interest of extensibility, we also include here a record of our implementation of
the integral calculations for use with random variable distributions, though they are not
currently used in our piecewise-linear implementation.
u(t) =
Z ∞
T
(1 − Φ(t))dt,UX ≤ T ≤ ∞
Deﬁne coeffO =
√
2σO
2 , lo =
t−µO
σO
√
2, and up =
maxdoselev−µO
σO
√
2 . The integral is calculated
as follows:
u(t) =
maxdoselev − t
2
+ coeffO ∗
 
lo

2errorf(lo
√
2) − 1

+
e−lo2
√
π
− up

2errorf(up
√
2) − 1

−
e−up2
√
π
!
,
v(t) =
Z T
0
Ψ(t)dt,0 ≤ T ≤ LY
Deﬁne coeffP =
√
2σP
2 , lo =
−µP
σP
√
2, and up =
t−µP
σP
√
2. The integral is calculated as
follows:
v(t) =
t
2
+coeffP
 
up

2errorf(up
√
2) − 1

+
e−up2
√
π
− lo

2errorf(lo
√
2) − 1

−
e−lo
√
π
!
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